share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K：外国发行人报告
美股SEC公告 ·  09/03 06:05
Moomoo AI 已提取核心信息
Alterity Therapeutics Limited, a development stage enterprise, has announced the cessation of a significant number of its securities. Specifically, 1,935,759,704 options, identified by the ASX security code ATHAAI and expiring on August 31, 2024, have ceased due to the expiry of the option without exercise or conversion. The cessation took place on August 31, 2024, and no consideration was paid by the entity for the cessation. Following this event, Alterity Therapeutics has updated its issued capital structure, which now comprises 5,320,336,118 ordinary fully paid shares and various classes of options with different expiry dates and exercise prices. The announcement was made on September 2, 2024, and is in accordance with the rules and regulations of the Securities Exchange Act of 1934. The company's issued capital information is crucial for investors as it affects the total market capitalization and share value.
Alterity Therapeutics Limited, a development stage enterprise, has announced the cessation of a significant number of its securities. Specifically, 1,935,759,704 options, identified by the ASX security code ATHAAI and expiring on August 31, 2024, have ceased due to the expiry of the option without exercise or conversion. The cessation took place on August 31, 2024, and no consideration was paid by the entity for the cessation. Following this event, Alterity Therapeutics has updated its issued capital structure, which now comprises 5,320,336,118 ordinary fully paid shares and various classes of options with different expiry dates and exercise prices. The announcement was made on September 2, 2024, and is in accordance with the rules and regulations of the Securities Exchange Act of 1934. The company's issued capital information is crucial for investors as it affects the total market capitalization and share value.
Alterity Therapeutics Limited，一家处于发展阶段的企业，宣布终止了大量的证券。具体而言，标记为ATHAAI的1,935,759,704份期权在2024年8月31日到期，由于未行使或转换选项，这些期权已经终止。终止事件发生在2024年8月31日，企业为此不做任何支付。在此事件后，Alterity Therapeutics已经更新了其已发行的资本结构，现在包括5,320,336,118股普通全额支付股份和具有不同到期日期和行使价格的各类期权。该公告于2024年9月2日发布，符合1934年证券交易法的规定和规章制度。公司的已发行资本信息对投资者来说至关重要，因为它影响着总市值和股票价值。
Alterity Therapeutics Limited，一家处于发展阶段的企业，宣布终止了大量的证券。具体而言，标记为ATHAAI的1,935,759,704份期权在2024年8月31日到期，由于未行使或转换选项，这些期权已经终止。终止事件发生在2024年8月31日，企业为此不做任何支付。在此事件后，Alterity Therapeutics已经更新了其已发行的资本结构，现在包括5,320,336,118股普通全额支付股份和具有不同到期日期和行使价格的各类期权。该公告于2024年9月2日发布，符合1934年证券交易法的规定和规章制度。公司的已发行资本信息对投资者来说至关重要，因为它影响着总市值和股票价值。
有用
没用

该公告为独立文件：

独立文件1

独立文件2

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息